1887

Abstract

The transmission of viral and non-viral infectious pathogens continues to be the most serious of the potential adverse effects of allogenic tissue transplantations. EU Directive 2006/17/EC stipulates that cadaveric blood specimens for serology testing in the context of post-mortem tissue donation must be taken not later than 24 h post-mortem. An expanded time slot would significantly improve the availability of tissue donations, but there are no significant data on the stability of infectious serology assays for anti-human immunodeficiency virus (HIV), anti-hepatitis C virus (HCV), hepatitis B virus (HBV) surface antigen (HBsAg) and anti-HBC core antigen (HBc) in samples collected more than 24 h post-mortem. In this prospective study, serum samples of 30 deceased persons were taken upon admission to the Institute of Forensic Medicine (University Hospital Hamburg-Eppendorf, Germany) and at 12, 24, 36 and 48 h post-mortem. All samples were measured twice, first using the Abbott AxSYM system, and then after ~9 months of storage at −70 °C using the BEP III System with Siemens and Ortho reagents. For HIV, six deceased persons with a pre-mortem HIV history were included. All samples (at committal and at 12, 24, 36, 48 h) were reactive. Indeterminate or false-negative results did not occur. For HCV, 17 deceased persons with a pre-mortem HCV history were included; 16 samples were reactive up to 48 h and one was reactive at 36 h post-mortem (48 h sample was not available). Indeterminate or false-negative results did not occur. For HBV, nine deceased persons were included: five samples were initially positive for HBsAg and remained positive up to 48 h, and eight of the samples were reactive for anti-HBc up to 48 h and one up to 36 h post-mortem (48 h sample was not available). Indeterminate or false-negative results did not occur. These data suggest that infectious serological testing may be extended for blood samples of potential tissue donors collected up to 48 h post-mortem to detect antibodies or antigens for HIV, HBV and HCV.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.027763-0
2011-07-01
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/jmm/60/7/920.html?itemId=/content/journal/jmm/10.1099/jmm.0.027763-0&mimeType=html&fmt=ahah

References

  1. Challine D., Roudot-Thoraval F., Sabatier P., Dubernet F., Larderie P., Rigot P., Pawlotsky J. M. 2006; Serological viral testing of cadaveric cornea donors. Transplantation 82:788–793 [View Article][PubMed]
    [Google Scholar]
  2. Essex M., Allan J., Kanki P., McLane M. F., Malone G., Kitchen L., Lee T. H. 1985; Antigens of human T-lymphotropic virus type III/lymphadenopathy-associated virus. Ann Intern Med 103:700–703[PubMed] [CrossRef]
    [Google Scholar]
  3. European Union 2004; Directive 2004/23/EC of the European Parliament and of the Council of 31 March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells.. Official Journal of the European Union 04.07.2004 10248–58
    [Google Scholar]
  4. European Union 2006; Commission Directive 2006/17/EC of 8 February 2006 implementing Directive 2004/23/EC of the European Parliament and of the Council as regards certain technical requirements for the donation, procurement and testing of human tissues and cells.. Official Journal of the European Union 02.09.2006 3840–52
    [Google Scholar]
  5. Federal Ministry of Justice 2010; Report of the German Government about the Supply with Tissues and Tissue Preparations in Germany (Article 7a GewG). 1008 2010 http://www.bmg.bund.de/fileadmin/redaktion/pdf_misc/Bericht-BReg-Gewebe.pdf
  6. Heim A., Wagner D., Rothämel T., Hartmann U., Flik J., Verhagen W. 1999; Evaluation of serological screening of cadaveric sera for donor selection for cornea transplantation. J Med Virol 58:291–295 [View Article][PubMed]
    [Google Scholar]
  7. Kitchen A. D., Newham J. A. 2011; Qualification of serological infectious disease assays for the screening of tissue samples from deceased donors. Cell Tissue Bank (Epub ahead of print) [View Article][PubMed]
    [Google Scholar]
  8. Laycock K. A., Essary L. R., Delaney S., Kuhns M. C., Pepose J. S. 1997; A critical evaluation of hepatitis C testing of cadaveric corneal donors. Cornea 16:146–150 [View Article][PubMed]
    [Google Scholar]
  9. Pepose J. S., MacRae S., Quinn T. C., Ward J. W. 1987; Serologic markers after the transplantation of corneas from donors infected with human immunodeficiency virus. Am J Ophthalmol 103:798–801[PubMed] [CrossRef]
    [Google Scholar]
  10. Pepose J. S., Buerger D. G., Paul D. A., Quinn T. C., Darragh T. M., Donegan E. 1992; New developments in serologic screening of corneal donors for HIV-1 and hepatitis B virus infections. Ophthalmology 99:879–888[PubMed] [CrossRef]
    [Google Scholar]
  11. Pruss A., Caspari G., Krüger D. H., Blümel J., Nübling C. M., Gürtler L., Gerlich W. H. 2010; Tissue donation and virus safety: more nucleic acid amplification testing is needed. Transpl Infect Dis 12:375–386 [View Article][PubMed]
    [Google Scholar]
  12. Püschel K., Mohsenian F., Laufs R., Polywka S., Ermer M. 1991; Postmortem viability of the human immunodeficiency virus. Int J Legal Med 104:109–110 [View Article][PubMed]
    [Google Scholar]
  13. Yao F., Seed C., Farrugia A., Morgan D., Cordner S., Wood D., Zheng M. H. 2007; The risk of HIV, HBV, HCV and HTLV infection among musculoskeletal tissue donors in Australia. Am J Transplant 7:2723–2726 [View Article][PubMed]
    [Google Scholar]
  14. Zou S., Dodd R. Y., Stramer S. L., Strong D. M. for the Tissue Safety Study Group 2004; Probability of viremia with HBV, HCV, HIV, and HTLV among tissue donors in the United States. N Engl J Med 351:751–759 [View Article][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.027763-0
Loading
/content/journal/jmm/10.1099/jmm.0.027763-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error